PMID: 9532518Apr 9, 1998Paper

Clinical overview of irbesartan: expanding the therapeutic window in hypertension

Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
A J Man in't Veld

Abstract

The clinical management of hypertension has traditionally been hampered by a limited therapeutic window, which has resulted in the maintenance of patients on doses of antihypertensive agents that often produce clinically significant side effects and suboptimal blood pressure control. To expand this window, a therapeutic agent must provide optimal, dose-related blood pressure control with placebo-like tolerability. Irbesartan, a new angiotensin II receptor antagonist, has been shown to provide significant blood pressure reductions compared with placebo and equal or better reductions compared with major antihypertensive agents of other classes. These effects have been demonstrated in an extensive clinical trials program, comprising 1691 irbesartan-treated patients and 539 placebo-treated patients. Active-drug-controlled trials with beta-blockers, angiotensin converting enzyme inhibitors, calcium antagonists and diuretics have further confirmed the excellent results with irbesartan. Moreover, irbesartan demonstrates a clear dose-related therapeutic response with no dose-related effects on adverse event rates. The clear advantages of irbesartan over antihypertensive agents of other classes have the potential to expand the therapeut...Continue Reading

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
Bernard Waeber, H R Brunner
© 2022 Meta ULC. All rights reserved